Current treatment regimens for inhalation injury are mainly supportive and rely on self-regeneration processes for recovery. Cell therapy with mesenchymal stromal cells (MSCs) is increasingly being investigated for the treatment of inhalation injury. Human amniotic MSCs (hAMSCs) were used in this study due to their potential use in inflammatory and fibrotic conditions of the lung. This study aimed at demonstrating that hAMSCs can be atomized with high viability, for the purpose of achieving a more uniform distribution of cells throughout the lung. Another aim of this study was to set ground for future application to healthy and diseased lungs by demonstrating that hAMSCs were able to survive after being sprayed onto substrates with different stiffness.
Methods:
Two methods of atomization were evaluated, and the LMA MAD780 device was selected for atomizing hAMSCs for optimized delivery. To mimic the stiffness of healthy and diseased lungs, gelatin gel (10% w/v) and tissue culture plastic were used as preliminary models. Poly-l-lysine (PLL) and collagen I coatings were used as substrates on which the hAMSCs were cultured after being sprayed.
Results:
The feasibility of atomizing hAMSCs was demonstrated with high cell viability (81 ± 3.1% and 79 ± 11.6% for cells sprayed onto plastic and gelatin, respectively, compared with 85 ± 4.8% for control/nonsprayed cells) that was unaffected by the different stiffness of substrates. The presence of the collagen I coating on which the sprayed cells were cultured yielded higher cell proliferation compared with both PLL and no coating. The morphology of sprayed cells was minimally compromised in the presence of the collagen I coating.
Conclusions:
This study demonstrated that hAMSCs are able to survive after being sprayed onto substrates with different stiffness, especially in the presence of collagen I. Further studies may advance the effectiveness of cell therapy for lung regeneration.
Get full access to this article
View all access options for this article.
References
1.
LeeJW, FangX, KrasnodembskayaA, HowardJP, and MatthayMA: Concise review: Mesenchymal stem cells for acute lung injury: Role of paracrine soluble factors. Stem Cells. 2011; 29:913–919.
2.
LauAN, GoodwinM, KimCF, and WeissDJ: Stem cells and regenerative medicine in lung biology and diseases. Mol Ther. 2012; 20:1116–1130.
3.
LimR, TanJL, and WallaceEM: Cell Therapies for Lung Disease, Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, 4th ed. CRC Press, Taylor & Francis Group, Boca Raton, FL; pp. 1157–1170, 2015.
4.
ZhuF, WangJ, QiuX, LiJ, and XiaZ: Smoke inhalation injury repaired by a bone marrow-derived mesenchymal stem cell paracrine mechanism: Angiogenesis involving the Notch signaling pathway. J Trauma Acute Care Surg. 2015; 78:565–572.
5.
GarciaO, and WarburtonD: Amniotic Fluid Stem Cell Therapy for Lung Disease, Perinatal Stem Cells. Springer, New York, NY; pp. 59–65, 2014.
6.
WeiX, YangX, HanZP, QuFF, ShaoL, and ShiYF: Mesenchymal stem cells: A new trend for cell therapy. Acta Pharmacol Sin. 2013; 34:747–754.
7.
DochevaD, PopovC, MutschlerW, and SchiekerM: Human mesenchymal stem cells in contact with their environment: Surface characteristics and the integrin system. J Cell Mol Med. 2007; 11:21–38.
8.
MillerAC, ElaminEM, and SuffrediniAF: Inhaled anticoagulation regimens for the treatment of smoke inhalation-associated acute lung injury: A systematic review. Crit Care Med. 2014; 42:413–419.
9.
SharmaA, and LunawatA: Role of heparin and N-acetylcystein in prevention of acute respiratory distress syndrome in suspected inhalation injury in burn. Indian J Basic Appl Med Res. 2015; 4:337–343.
XuF, HuY, ZhouJ, and WangX: Mesenchymal stem cells in acute lung injury: Are they ready for translational medicine?. J Cell Mol Med. 2013; 17:927–935.
12.
JohnsonER, and MatthayMA: Acute lung injury: Epidemiology, pathogenesis, and treatment. J Aerosol Med Pulm Drug Deliv. 2010; 23:243–252.
13.
ChenX, LiuQ, WangD, FengS, ZhaoY, ShiY, and LiuQ: Protective effects of hydrogen-rich saline on rats with smoke inhalation injury. Oxid Med Cell Longev. 2015; 2015:106836.
14.
MatthayMA, GoolaertsA, HowardJP, and LeeJW: Mesenchymal stem cells for acute lung injury: Preclinical evidence. Criti Care Med. 2010; 38:S569–S573.
15.
AntunesMA, AbreuSC, CruzFF, TeixeiraAC, Lopes-PachecoM, BandeiraE, OlsenPC, DiazBL, TakyiaCM, FreitasIPRG, RochaNN, CapelozziVL, XistoDG, WeissDJ, MoralesMM, and RoccoPRM: Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema. Respir Res. 2014; 15:118.
16.
HaoQ, ZhuYG, MonselA, GennaiS, LeeT, XuF, and LeeJW: Study of bone marrow and embryonic stem cell-derived human mesenchymal stem cells for treatment of Escherichia coli endotoxin-induced acute lung injury in mice. Stem Cells Transl Med. 2015; 4:832–840.
17.
IsmailSN, PolakJM, and MantalarisA: Lung Stem Cell Bioprocessing: Fundamentals of Producing Lung Cells, Cell Therapy for Lung Disease. Imperial College Press, London, UK; pp. 173–177, 2010.
18.
AlvianoF, FossatiV, MarchionniC, ArpinatiM, BonsiL, FranchinaM, LanzoniG, CantoniS, CavalliniC, BianchiF, TazzariP, PasquinelliG, ForoniL, VenturaC, GrossiA, and BagnaraG: Term amniotic membrane is a high throughput source for multipotent mesenchymal stem cells with the ability to differentiate into endothelial cells in vitro. BMC Dev Biol. 2007; 7:11.
19.
ParacchiniV, CarboneA, ColomboF, CastellaniS, MazzucchelliS, Di GioiaS, DegiorgioD, SeiaM, PorrettiL, ColomboC, and ConeseM: Amniotic mesenchymal stem cells: A new source for hepatocyte-like cells and induction of CFTR expression by coculture with cystic fibrosis airway epithelial cells. J Biomed Biotechnol. 2012; 2012:575471.
20.
WallaceEM, CargnoniA, LimR, HodgeA, and SievertW: The Use of Placenta-Derived Cells in Inflammatory and Fibrotic Disorders, Placenta: The Tree of Life. CRC Press, Boca Raton, FL; pp. 181–196, 2016.
21.
CarusoM, EvangelistaM, and ParoliniO: Human term placental cells: Phenotype, properties and new avenues in regenerative medicine. Int J Mol Cell Med. 2012; 1:64–74.
22.
MoodleyY, VaghjianiV, ChanJ, BalticS, RyanM, TchongueJ, SamuelCS, MurthiP, ParoliniO, and ManuelpillaiU: Anti-inflammatory effects of adult stem cells in sustained lung injury: A comparative study. PLoS One. 2013; 8:e69299.
23.
CargnoniA, GibelliL, TosiniA, SignoroniPB, NassuatoC, ArientiD, LombardiG, AlbertiniA, WenglerGS, and ParoliniO: Transplantation of allogeneic and xenogeneic placenta-derived cells reduces bleomycin-induced lung fibrosis. Cell Transplant. 2009; 18:405–422.
24.
SiliniA, ParoliniO, HuppertzB, and LangI: Soluble factors of amnion-derived cells in treatment of inflammatory and fibrotic pathologies. Curr Stem Cell Res Ther. 2013; 8:6–14.
25.
CargnoniA, PiccinelliEC, ResselL, RossiD, MagattiM, ToschiI, CesariV, AlbertiniM, MazzolaS, and ParoliniO: Conditioned medium from amniotic membrane-derived cells prevents lung fibrosis and preserves blood gas exchanges in bleomycin-injured mice-specificity of the effects and insights into possible mechanisms. Cytotherapy. 2014; 16:17–32.
26.
CarraroG, PerinL, SedrakyanS, GiulianiS, TiozzoC, LeeJ, TurcatelG, De LangheSP, DriscollB, BellusciS, MinooP, AtalaA, De FilippoRE, and WarburtonD: Human amniotic fluid stem cells can integrate and differentiate into epithelial lung lineages. Stem Cells. 2008; 26:2902–2911.
27.
CurleyGF, AnsariB, HayesM, DevaneyJ, MastersonC, RyanA, BarryF, O'BrienT, TooleDO, and LaffeyJG: Effects of intratracheal mesenchymal stromal cell therapy during recovery and resolution after ventilator-induced lung injury. Anesthesiology. 2013; 118:924–932.
28.
LeblondA-L, NaudP, ForestV, GourdenC, SaganC, RomefortB, MathieuE, DelormeB, CollinC, PagèsJ-C, SensebéL, PitardB, and LemarchandP: Developing cell therapy techniques for respiratory disease: Intratracheal delivery of genetically engineered stem cells in a murine model of airway injury. Hum Gene Ther. 2009; 20:1329–1343.
29.
Serrano-MollarA, NacherM, Gay-JordiG, ClosaD, XaubetA, and BulbenaO: Intratracheal transplantation of alveolar type II cells reverses bleomycin-induced lung fibrosis. Am J Respir Crit Care Med. 2007; 176:1261–1268.
30.
Van HaaftenT, ByrneR, BonnetS, RochefortGY, AkabutuJ, BouchentoufM, Rey-ParraGJ, GalipeauJ, HaromyA, EatonF, ChenM, HashimotoK, AbleyD, KorbuttG, ArcherSL, and ThebaudB: Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med. 2009; 180:1131–1142.
31.
KimES, ChangYS, ChoiSJ, KimJK, YooHS, AhnSY, SungDK, KimSY, ParkYR, and ParkWS: Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells attenuates Escherichia coli-induced acute lung injury in mice. Respir Res. 2011; 12:108.
32.
TibboelJ, KeijzerR, ReissI, de JongsteJC, and PostM: Intravenous and intratracheal mesenchymal stromal cell injection in a mouse model of pulmonary emphysema. J Chron Obstruct Pulmon Dis. 2013; 11:310–318.
33.
GuiL, QianH, RoccoKA, GrecuL, and NiklasonLE: Efficient intratracheal delivery of airway epithelial cells in mice and pigs. Am J Physiol Lung Cell Mol Physiol. 2015; 308:L221–L228.
34.
ZhangS, DanchukSD, ImhofKMP, SemonJA, ScruggsBA, BonvillainRW, StrongAL, GimbleJM, BetancourtAM, SullivanDE, and BunnellBA: Comparison of the therapeutic effects of human and mouse adipose-derived stem cells in a murine model of lipopolysaccharide-induced acute lung injury. Stem Cell Res Ther. 2013; 4:13.
35.
DanchukS, YlostaloJH, HossainF, SorgeR, RamseyA, BonvillainRW, LaskyJA, BunnellBA, WelshDA, ProckopDJ, and SullivanDE: Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-α-induced protein 6. Stem Cell Res Ther. 2011; 2:27.
36.
KardiaE, YusoffNM, ZakariaZ, and YahayaB: Aerosol-based delivery of fibroblast cells for treatment of lung diseases. J Aerosol Med Pulm Drug Deliv. 2014; 27:30–34.
37.
GhadiriM, YoungPM, and TrainiD: Cell-based therapies for the treatment of idiopathic pulmonary fibrosis (IPF) disease. Expert Opin Biol Ther. 2016; 16:375–387.
38.
FalangaV, IwamotoS, ChartierM, YufitT, ButmarcJ, KouttabN, ShrayerD, and CarsonP: Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng. 2007; 13:1299–1312.
39.
EbenspergerR: Spray formulation of mesenchymal stem cells for the treatment of chronic wounds. Google Pat., 2014. Patent number EP2743343 A1.
40.
SosnowskiT, KurowskaA, ButrukB, and JablczynskaK: Spraying of cell colloids in medical atomizers. AIDIC Conf Ser. 2013; 11:371–380.
41.
BraghirolliDI, ZamboniF, ChagastellesPC, MouraDJ, SaffiJ, HenriquesJA, PilgerDA, and PrankeP: Bio-electrospraying of human mesenchymal stem cells: An alternative for tissue engineering. Biomicrofluidics. 2013; 7:44130.
42.
KimSY, WongAH, Abou NeelEA, ChrzanowskiW, and ChanHK: The future perspectives of natural materials for pulmonary drug delivery and lung tissue engineering. Expert Opin Drug Deliv. 2015; 12:869–887.
43.
HaghiM, TrainiD, WoodLG, OliverB, YoungPM, and ChrzanowskiW: A ‘soft spot’ for drug transport: Modulation of cell stiffness using fatty acids and its impact on drug transport in lung model. J Mater Chem B. 2015; 3:2583–2589.
44.
XinH, SunR, KanehiraM, TakahataT, ItohJ, MizuguchiH, and SaijoY: Intratracheal delivery of CX3CL1-expressing mesenchymal stem cells to multiple lung tumors. Mol Med. 2009; 15:321–327.
45.
CaiSX, LiuAR, ChenS, HeHL, ChenQH, XuJY, PanC, YangY, GuoFM, HuangYZ, LiuL, and QiuHB: Activation of Wnt/β-catenin signalling promotes mesenchymal stem cells to repair injured alveolar epithelium induced by lipopolysaccharide in mice. Stem Cell Res Ther. 2015; 6:65.
46.
GuW, SongL, LiXM, WangD, GuoXJ, and XuWG: Mesenchymal stem cells alleviate airway inflammation and emphysema in COPD through down-regulation of cyclooxygenase-2 via p38 and ERK MAPK pathways. Sci Rep. 2015; 5:8733.
47.
Hasegawa-BabaY, KubotaH, TakataA, and MiyagawaM: Intratracheal instillation methods and the distribution of administered material in the lung of the rat. J Toxicol Pathol. 2014; 27:197–204.
48.
Garcia-ContrerasL, MorçölT, BellSJD, and HickeyAJ: Evaluation of novel particles as pulmonary delivery systems for insulin in rats. AAPS PharmSci. 2003; 5:10–20.
49.
RustadKC, and GurtnerGC: Mesenchymal stem cells home to sites of injury and inflammation. Adv Wound Care. 2012; 1:147–152.
50.
FreyerAM, JohnsonSR, and HallIP: Effects of growth factors and extracellular matrix on survival of human airway smooth muscle cells. Am J Respir Cell Mol Biol. 2001; 25:569–576.
51.
MaziaD, SchattenG, and SaleW: Adhesion of cells to surfaces coated with polylysine. Applications to electron microscopy. J Cell Biol. 1975; 66:198–200.
52.
Fischer-CrippsAC: Nanoindentation Test Standards, Nanoindentation. Springer, New York, NY; pp. 181–198, 2011.
53.
Gonzalez-LopezA, and AlbaicetaG: Repair after acute lung injury: Molecular mechanisms and therapeutic opportunities. Crit Care. 2012; 16:209.
54.
HirstSJ, TwortCH, and LeeTH: Differential effects of extracellular matrix proteins on human airway smooth muscle cell proliferation and phenotype. Am J Respir Cell Mol Biol. 2000; 23:335–344.
55.
DekkersBGJ, SchaafsmaD, NelemansSA, ZaagsmaJ, and MeursH: Extracellular matrix proteins differentially regulate airway smooth muscle phenotype and function. Am J Physiol Lung Cell Mol Physiol. 2007; 292:L1405–L1413.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
